Oct 24 (Reuters) - Bubs Australia (BUB) :
- BUBS INFANT FORMULA Q1 GROSS REVENUE OF A$17.5M, UP 41% ON PCP
- US FDA PERMANENT ACCESS PROCESS REMAINS ON TRACK WITH CLINICAL TRIAL UNDERWAY
- Q1 GROUP GROSS REVENUE OF A$24.3MLN, UP 3.4% PRIOR CORRESPONDING PERIOD
- MAKING SIGNIFICANT INVESTMENT AND INCURRING SIGNIFICANT COSTS ASSOCIATED WITH FDA APPROVAL PROCESS OF A$2.9M IN Q1 FY24
- FDA APPROVAL COSTS WHILST ONE-OFF AND NON-RECURRING IN NATURE, WILL CONTINUE THROUGHOUT FY24 ALBEIT FRONT END LOADED
News: BUB Bubs Australia Says Bubs Infant Formula Q1 Gross Revenue Of A$17.5M, Up 41% On Pcp
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $142.9M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 16.5¢ | 15.8¢ | $240.2K | 1.490M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 404981 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 82249 | 7 |
View Market Depth
| Last trade - 16.15pm 30/07/2025 (20 minute delay) ? |
| BUB (ASX) Chart |